Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

20012,717 citationsJournal Articlebronze Open Access

Authors

The BCR-ABL tyrosine kinase inhibitor STI571 is well tolerated and has substantial activity in the blast crises of CML and in Ph-positive ALL.

Good health and well-being

Published in: New England Journal of Medicine

Volume 344, Issue 14, pp. 1038-1042

Field-Weighted Citation Impact: 107.41